Global registry for Takayasu arteritis patients
Part of Heart & circulation, Skin clinical trials.
This study collects medical information from patients diagnosed with Takayasu arteritis, a rare disease affecting large blood vessels. By joining, you help researchers better understand this condition and improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Takayasu arteritis (confirmed by standard medical criteria)
- You must be willing to share your medical history and any health changes with the research team
- You must sign a written consent form showing you understand the study and agree to participate
- You must be able to follow the study requirements for the duration you're enrolled
- If you are under 18, your parent or legal guardian must also agree and sign the consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information and blood samples (biomarkers) to better understand Takayasu arteritis and how active it is. It may help researchers find tests that support diagnosis and track disease activity.
This study tests whether ultrasound can track inflammation in blood vessels for people with Takayasu arteritis (a rare condition causing vessel inflammation). You'll have regular ultrasounds to see if this method helps doctors spot disease activity early.
This UK-based study uses a questionnaire to learn about how people with Takayasu arteritis (a rare type of vasculitis) are treated and what they think about their care. If you have TAK, your answers can help doctors understand how to better manage this condition.
This study tests two new medications, vunakizumab and ivarmacitinib, for people with active Takayasu's arteritis (TAK) that is not fully controlled by standard treatments. The goal is to see if these drugs are safe and effective for reducing disease activity.
This study tests a new pill called deucravacitinib for people with active Takayasu's arteritis (a rare blood vessel disease). It aims to see if the drug can help control inflammation when other treatments have not worked well enough.
This study looks at different types of blood vessel inflammation (vasculitis) to learn more about why they happen and how they progress. By joining, you may help doctors better understand these conditions and improve future treatments.
Hear when a new Takayasu Arteritis (TAK) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.